ReviewInnere Medizin (Heidelberg, Germany)2026
[New oral anti-obesity drugs: the future or second choice?]
Review in Innere Medizin (Heidelberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obesity and its comorbidities represent a growing worldwide health challenge. To date, lifestyle modification is the most frequently used treatment modality, but offers only limited success in terms of both the extent and maintenance of weight loss. Potent injectable incretin mimetics such as semaglutide and tirzepatide were recently introduced as novel pharmacological options for improved and clinically meaningful weight management. In 2026, the first two oral glucagon-like peptide‑1 (GLP-1)-based agents, namely oral semaglutide and orforglipron, were approved and are promoted as alternative drug choices for additional weight loss, allowing people with obesity to make their own choice from a broader spectrum of therapeutics. This review describes the current state of knowledge on these new medications for the treatment of obesity. A variety of other oral drugs is currently under development and will substantially expand obesity management in the coming years.
Indexed as
Identifiers
42977781What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.